title: From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report.
abstract: BACKGROUND
  Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is associated with poorer response to chemotherapy and chemoradiotherapy.
  
  
  METHODS
  A 27-year-old Swedish woman presented with stomach pain and weight loss, and was diagnosed with locally advanced MAC in the transverse colon as well as 3 liver metastases. Neoadjuvant treatment with fluorouracil, folinic acid and oxaliplatin (FLOX) failed due to several infections, pulmonary embolism and deteriorated performance status. The patient was therefore considered palliative. Palliative treatment with metronomic capecitabine 500 mg × 2 daily and bevacizumab every other week were initiated. After 4 months of treatment the tumors had regressed and the patient was able to undergo radical surgery, thereby changing the treatment intention from palliative to curative. No adjuvant chemotherapy was given. There were no signs of recurrence 9 months later.
  
  
  CONCLUSIONS
  The role of the combination of metronomic capecitabine and bevacizumab in patients with MAC merits further investigation.
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. karolina.vernmark@regionostergotland.se.|Department of Oncology, Linköping University, S-58185, Linköping, Sweden. karolina.vernmark@regionostergotland.se.
authors.forename: Karolina
authors.initials: K
authors.lastname: Vernmark
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. maria.albertsson@regionostergotland.se.|Department of Oncology, Linköping University, S-58185, Linköping, Sweden. maria.albertsson@regionostergotland.se.
authors.forename: Maria
authors.initials: M
authors.lastname: Albertsson
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. bergthor.bjornsson@regionostergotland.se.|Departement of Surgery, Linköping University, Linköping, Sweden. bergthor.bjornsson@regionostergotland.se.
authors.forename: Bergthor
authors.initials: B
authors.lastname: Björnsson
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. thomas.gasslander@regionostergotland.se.|Departement of Surgery, Linköping University, Linköping, Sweden. thomas.gasslander@regionostergotland.se.
authors.forename: Thomas
authors.initials: T
authors.lastname: Gasslander
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. per.sandstrom@regionostergotland.se.|Departement of Surgery, Linköping University, Linköping, Sweden. per.sandstrom@regionostergotland.se.
authors.forename: Per
authors.initials: P
authors.lastname: Sandström
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. xiao-feng.sun@liu.se.
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Sun
authors.affiliation: Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. annika.holmqvist@regionostergotland.se.|Department of Oncology, Linköping University, S-58185, Linköping, Sweden. annika.holmqvist@regionostergotland.se.
authors.forename: Annika
authors.initials: A
authors.lastname: Holmqvist
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab / Q000008:administration & dosage*; D000069287:Capecitabine / Q000008:administration & dosage*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010166:Palliative Care
chemical_list: D000068258:Bevacizumab; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil